AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Glutamate receptor ionotropic, NMDA 2C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14957

UPID:

NMDE3_HUMAN

Alternative names:

Glutamate [NMDA] receptor subunit epsilon-3; N-methyl D-aspartate receptor subtype 2C

Alternative UPACC:

Q14957; B2RTT1

Background:

The Glutamate receptor ionotropic, NMDA 2C, also known as Glutamate [NMDA] receptor subunit epsilon-3 and N-methyl D-aspartate receptor subtype 2C, plays a pivotal role in neural communication. It is a component of NMDA receptor complexes, crucial for high calcium permeability and voltage-dependent sensitivity to magnesium. Activation of this receptor is essential for synaptic plasticity, contributing to learning and memory by regulating excitatory and inhibitory activities in the prefrontal cortex.

Therapeutic significance:

Understanding the role of Glutamate receptor ionotropic, NMDA 2C could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.